SUN-LB080 ACROSTUDY - Safety and Efficacy of a Cohort of 110 Naïve Patients with Acromegaly Treated with Pegvisomant

Background:  ACROSTUDY is an open-label, non-interventional post-authorization safety study that began in 2004 to evaluate safety in at least 1000 acromegaly patients treated with the GH receptor antagonist pegvisomant (PEGV).  This commitment was fulfilled in Jan 2013. ACROSTUDY w...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Endocr Soc
Main Authors: Wajnrajch, Michael, Gomez, Roy, Hey-Hadavi, Judith, Kelepouris, Nicky, Lans, Joli, Loftus, Jane, Camacho-Hubner, Cecilia, Cara, Jose, Rao Valluri, Srinivas, Fleseriu, Maria, Salvatori, Roberto, Webb, Susan, Brue, Thierry, Palladino, Andrew
Formato: Artigo
Idioma:Inglês
Publicado em: Endocrine Society 2019
Assuntos:
Neuroendocrinology and Pituitary
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6553204/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-SUN-LB080
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados